Alison Conlin

6.5k total citations · 2 hit papers
73 papers, 1.8k citations indexed

About

Alison Conlin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Alison Conlin has authored 73 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Alison Conlin's work include Cancer Treatment and Pharmacology (28 papers), HER2/EGFR in Cancer Research (22 papers) and Advanced Breast Cancer Therapies (18 papers). Alison Conlin is often cited by papers focused on Cancer Treatment and Pharmacology (28 papers), HER2/EGFR in Cancer Research (22 papers) and Advanced Breast Cancer Therapies (18 papers). Alison Conlin collaborates with scholars based in United States, Canada and United Kingdom. Alison Conlin's co-authors include Andrew D. Seidman, Supriya G. Mohile, Erika Hamilton, Michelle C. Janelsins, Virginia F. Borges, Karen M. Mustian, Jorge Chaves, Todd Gray, Charles E. Heckler and Alex Vo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Alison Conlin

70 papers receiving 1.8k citations

Hit Papers

Cognitive Complaints in Survivors of Breast Cancer After ... 2017 2026 2020 2023 2017 2025 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study
    2017 270 citations Michelle C. Janelsins, Charles E. Heckler et al. Journal of Clinical Oncology profile →
  2. Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update
    2025 18 citations Ko Un Park, Mark R. Somerfield et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alison Conlin United States 23 1.1k 663 226 222 215 73 1.8k
Jing Huang China 22 1.1k 1.0× 655 1.0× 108 0.5× 277 1.2× 581 2.7× 110 2.2k
Jeong Eun Kim South Korea 25 1.2k 1.1× 530 0.8× 85 0.4× 348 1.6× 351 1.6× 176 2.2k
Matthew P. Mumber United States 10 894 0.8× 370 0.6× 96 0.4× 240 1.1× 123 0.6× 14 1.5k
Thomas Cerny Switzerland 25 921 0.8× 477 0.7× 80 0.4× 233 1.0× 568 2.6× 53 2.2k
Alexander DeVries Austria 17 472 0.4× 221 0.3× 152 0.7× 77 0.3× 105 0.5× 28 1.5k
Steve Kim United States 26 543 0.5× 335 0.5× 35 0.2× 310 1.4× 589 2.7× 64 2.3k
Johanna M.A. Pijnenborg Netherlands 32 801 0.7× 262 0.4× 34 0.2× 310 1.4× 398 1.9× 160 3.1k
Xavier Quantin France 23 981 0.9× 766 1.2× 59 0.3× 234 1.1× 394 1.8× 115 1.9k
D. Lynne Smith United States 25 799 0.7× 228 0.3× 75 0.3× 342 1.5× 1.0k 4.8× 76 2.4k
Renato V. LaRocca United States 18 418 0.4× 341 0.5× 421 1.9× 143 0.6× 297 1.4× 47 1.4k

Countries citing papers authored by Alison Conlin

Since Specialization
Citations

This map shows the geographic impact of Alison Conlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Conlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Conlin more than expected).

Fields of papers citing papers by Alison Conlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Conlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Conlin. The network helps show where Alison Conlin may publish in the future.

Co-authorship network of co-authors of Alison Conlin

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Conlin. A scholar is included among the top collaborators of Alison Conlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Conlin. Alison Conlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Ko Un, Mark R. Somerfield, Muriel Brackstone, et al.. (2025). Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 43(14). 1720–1741. 18 indexed citations breakdown →
2.
Tolaney, Sara M., Komal Jhaveri, Teresa Helsten, et al.. (2025). Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study. Frontiers in Oncology. 15. 1555921–1555921.
3.
Altman, Brian J., Po‐Ju Lin, Chin‐Shang Li, et al.. (2025). Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia. PubMed. 3(1). 60–60. 1 indexed citations
4.
5.
6.
Peterson, Derick R., Richard F. Dunne, Eva Culakova, et al.. (2023). Association of nutrition with psychological health and quality of life among older adults with advanced cancer.. Journal of Clinical Oncology. 41(16_suppl). 12043–12043. 1 indexed citations
7.
Tolaney, Sara M., Muralidhar Beeram, J. Thaddeus Beck, et al.. (2022). Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in Oncology. 11. 810023–810023. 11 indexed citations
8.
Loh, Kah Poh, Paul R. Duberstein, Jason Zittel, et al.. (2019). Relationships of self-perceived age with geriatric assessment domains in older adults with cancer. Journal of Geriatric Oncology. 11(6). 1006–1010. 8 indexed citations
9.
Kleckner, Ian R., Charles Kamen, Calvin L. Cole, et al.. (2019). Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial. Supportive Care in Cancer. 27(12). 4615–4625. 37 indexed citations
10.
Murthy, Rashmi K., Virginia F. Borges, Alison Conlin, et al.. (2018). Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(7). 880–888. 129 indexed citations
11.
12.
Beeram, M., Sara M. Tolaney, J. Thaddeus Beck, et al.. (2016). A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 27. vi556–vi556. 8 indexed citations
13.
Peereboom, D., Conleth G. Murphy, Manmeet S. Ahluwalia, et al.. (2014). Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro-Oncology. 16(4). 579–583. 22 indexed citations
14.
Morris, Patrick G., Maurizio Fazio, Azeez Farooki, et al.. (2012). Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. Journal of Oral and Maxillofacial Surgery. 70(12). 2768–2775. 11 indexed citations
15.
Geraghty, Joe, Alison Conlin, T Gledhill, et al.. (2011). Multi-centre audit to determine factors associated with success and failure in treating colonic obstruction with self expanding metals stents (SEMS). Gut. 60(Suppl 1). A66.1–A66. 2 indexed citations
16.
Brogi, Edi, Conleth G. Murphy, Matthew Johnson, et al.. (2011). Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Annals of Oncology. 22(12). 2597–2603. 30 indexed citations
17.
Conlin, Alison, R. Steele, & C. Roland Wolf. (2008). Dusp1/mkp-1, dusp2/hpac1 and dusp8/vh5 expression in colorectal cancer. Gut. 57. 1 indexed citations
18.
Conlin, Alison & Andrew D. Seidman. (2007). Taxanes in breast cancer: An update. Current Oncology Reports. 9(1). 22–30. 38 indexed citations
19.
Conlin, Alison & Andrew D. Seidman. (2007). Use of the Oncotype DX™ 21-Gene Assay to Guide Adjuvant Decision Making in Early-Stage Breast Cancer. Molecular Diagnosis & Therapy. 11(6). 355–360. 14 indexed citations
20.
Conlin, Alison, et al.. (2005). The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 54(9). 1283–1286. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jing Huang Breakdown of academic impact, for papers by Jeong Eun Kim Breakdown of academic impact, for papers by Matthew P. Mumber Breakdown of academic impact, for papers by Thomas Cerny Breakdown of academic impact, for papers by Alexander DeVries Breakdown of academic impact, for papers by Steve Kim Breakdown of academic impact, for papers by Johanna M.A. Pijnenborg Breakdown of academic impact, for papers by Xavier Quantin Breakdown of academic impact, for papers by D. Lynne Smith Breakdown of academic impact, for papers by Renato V. LaRocca
Rankless by CCL
2026